Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio Inc is a genetic medicines company. The company is focused on developing transformative therapies for rare, monogenic CNS disorders. It has pipeline products such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease.
Enrolled 4 patients in Cohort 2 of the upliFT-D trial for FTD-GRN, with patient dosing advancing as planned; 12-month Cohort 1 and interim Cohort 2 data expected in 1H25 Updated interim data from...
PHILADELPHIA , Nov. 06, 2024 (GLOBE NEWSWIRE) -- Passage Bio, Inc. (NASDAQ: PASG), a clinical stage genetic medicines company focused on improving the lives of patients with neurodegenerative...
Preclinical data demonstrated that an AAV1 vector achieved superior human progranulin levels in the CSF as compared to AAV5 and AAVhu68 (an AAV9 variant) Nonclinical data showed PBFT02 improved...
기간 | 변동 | 변동 % | 시가 | 고가 | 저가 | 평균 일일 거래량 | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.2599 | 41.2474210443 | 0.6301 | 1.33 | 0.6301 | 4561043 | 1.09340319 | CS |
4 | 0.28 | 45.9016393443 | 0.61 | 1.33 | 0.451 | 1195551 | 0.98962189 | CS |
12 | 0.2 | 28.9855072464 | 0.69 | 1.33 | 0.451 | 551101 | 0.8868064 | CS |
26 | -0.19 | -17.5925925926 | 1.08 | 1.33 | 0.451 | 373816 | 0.86883455 | CS |
52 | 0.2234 | 33.5133513351 | 0.6666 | 1.79 | 0.451 | 417503 | 0.98432982 | CS |
156 | -6.82 | -88.4565499351 | 7.71 | 7.81 | 0.451 | 328689 | 1.67401249 | CS |
260 | -21.38 | -96.0035922766 | 22.27 | 38.23 | 0.451 | 318562 | 7.14082625 | CS |
도움 및 지원받기: kr-support@advfn.com
ADVFN 서비스 이용은 ADVFN의 이용약관에 동의하는 것입니다 이용약관